Effect of OPG gene mutation on protein expression and biological activity in osteoporosis

Qin,Shuhui; Zhang,Qiuping; Zhang,Li

doi:10.3892/etm.2017.4712

August-2017 Volume 14 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2017 Volume 14 Issue 2

Full Size Image

Article Open Access

Effect of OPG gene mutation on protein expression and biological activity in osteoporosis

Authors:
- Shuhui Qin
- Qiuping Zhang
- Li Zhang
View Affiliations / Copyright

Affiliations: Department of Orthopedics, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China, Department of Urinary Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China, Department of Endocrinology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China

Copyright: © Qin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 1475-1480
|
Published online on: June 28, 2017

https://doi.org/10.3892/etm.2017.4712
Expand metrics +

Abstract

The effect of an osteoprotegerin (OPG) gene mutation was investigated on its protein expression and biological activity in osteoporosis. The pcDNA3.0-OPG plasmid or wild-type plasmid were transfected into HEK293 cells. Osteoclast tartrate-resistant acid phosphatase (TRAP) staining and counting were then performed, and the expression of genes related to osteoclast differentiation and activation were measured by RT-PCR. The wild-type or mutant-type OPG at concentrations of 0, 10, 20, 50 and 100 ng/ml were added respectively to RAW264.7 cells and incubated for 24 h. The viability of cells treated with the wild-type and mutant-type OPG at a concentration of 100 ng/ml was still over 99%, which indicated that the wild-type and mutant-type OPG at this concentration had no cytotoxic effect on RAW264.7 cells. The number of TRAP-positive cells decreased with increasing concentration of wild-type or mutant-type OPG. At the concentrations of 20, 50 and 100 ng/ml, the inhibitory effect of wild-type OPG was significantly higher than that of mutant-type OPG (p<0.05). Both mutant-type and wild-type OPG inhibited the bone resorption activity of osteoclasts, and the inhibitory effect of wild-type OPG was significantly higher than that of mutant-type OPG at the concentrations of 20, 50 and 100 ng/ml (p<0.05). The levels of TRAP and RANK mRNA in the wild-type OPG treatment group were significantly lower than those in the control group, while the levels of TRAP and RANK mRNA in the mutant-type OPG treatment group were significantly lower than those in the wild-type group (p<0.05). The genetic mutation did not affect the protein expression levels of OPG, but inhibited the normal activity of OPG.

View Figures

View References

1	McCormick RK: Osteoporosis: Integrating biomarkers and other diagnostic correlates into the management of bone fragility. Altern Med Rev. 12:113–145. 2007.PubMed/NCBI
2	Riasnyĭ VM, Apukhovs'ka LI, Velykyĭ MM, Shymans'kyĭ IO, Labudzyns'kyĭ DO and Komisarenko SV: Immunomodulatory effects of vitamin D3 and bisphosphonates in nutritional osteoporosis in rats. Ukr Biokhim Zh (1999). 84:73–80. 2012.(In Ukrainian). PubMed/NCBI
3	Hwang JS, Chen JF, Yang TS, Wu DJ, Tsai KS, Ho C, Wu CH, Su SL, Wang CJ and Tu ST: The effects of strontium ranelate in Asian women with postmenopausal osteoporosis. Calcif Tissue Int. 83:308–314. 2008. View Article : Google Scholar : PubMed/NCBI
4	Hofbauer LC and Schoppet M: Osteoprotegerin gene polymorphism and the risk of osteoporosis and vascular disease. J Clin Endocrinol Metab. 87:4078–4079. 2002. View Article : Google Scholar : PubMed/NCBI
5	Ohmori H, Makita Y, Funamizu M, Hirooka K, Hosoi T, Orimo H, Suzuki T, Ikari K, Nakajima T, Inoue I, et al: Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis. J Hum Genet. 47:400–406. 2002. View Article : Google Scholar : PubMed/NCBI
6	Dominguez LJ, Scalisi R and Barbagallo M: Therapeutic options in osteoporosis. Acta Biomed. 81 Suppl 1:55–65. 2010.PubMed/NCBI
7	Montagnana M, Lippi G, Danese E and Guidi GC: The role of osteoprotegerin in cardiovascular disease. Ann Med. 45:254–264. 2013. View Article : Google Scholar : PubMed/NCBI
8	Brosch S, Redlich K and Pietschmann P: Pathogenesis of osteoporosis in rheumatoid arthritis. Acta Med Austriaca. 30:1–5. 2003.(In German). View Article : Google Scholar : PubMed/NCBI
9	Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, et al: Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 139:1329–1337. 1998. View Article : Google Scholar : PubMed/NCBI
10	Wright HL, McCarthy HS, Middleton J and Marshall MJ: RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med. 2:56–64. 2009. View Article : Google Scholar : PubMed/NCBI
11	Hofbauer LC, Kühne CA and Viereck V: The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact. 4:268–275. 2004.PubMed/NCBI
12	Khosla S: Minireview: The OPG/RANKL/RANK system. Endocrinology. 142:5050–5055. 2001. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Effect of OPG gene mutation on protein expression and biological activity in osteoporosis

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles